Two decades of studies of intraperitoneal therapy for persistent or recurrent ovarian carcinoma have clearly shown that the procedure is generally safe, particularly in experienced users. Further, ...

Since patients with peritoneal metastases often also have distant metastases in systemic organs, intravenous therapy is usually the standard of care. Multiple clinical studies have shown that adding ...

In this issue of the Journal of Clinical Oncology, three experienced and respected European clinical researchers present their viewpoint that intraperitoneal (IP) chemotherapy remains experimental in ...

Surgery and standard intravenous chemotherapy with a platinum–taxane combination induces complete remission in the majority of patients with newly diagnosed ovarian cancer. Most patients will ...

PATIENTS undergoing peritoneal dialysis frequently require antibiotic therapy for intraperitoneal and systemic infections. Since information concerning transperitoneal movement of antibiotics is ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Patients treated with combined hemodialysis and peritoneal dialysis from the start of renal ...

VS-01 is a novel liposomal-based intraperitoneal fluid that acts as a clearance enhancer of toxic metabolites, in particular ammonia, from the body. The Food and Drug Administration (FDA) has granted ...

Investigators have uncovered a new genetic cause of mesothelioma: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma. Unlike previously known causes, this ...

Drug delivery systems can alter drug clearance from the peritoneal cavity and drug toxicity profiles. For example, IP injection of cisplatin-loaded polymeric microspheres (100–200 µm, which releases ...